From diagnostics to drug delivery to regenerative medicine, extracellular vesicles (EVs) are the messengers of the moment, offering a promising glimpse of future applications to the biologists who study them and the longevity experts interested in their powerful signaling properties. No EV-based therapeutic product has yet been formally approved for marketing, but clinical evidence is building around possible applications for EVs in the future – and their implications for longevity and regenerative medicine.

Unique Sentinels

EVs are small membrane-bound particles released by cells. They carry proteins, lipids, nucleic acids, and other signaling molecules, and play an important role in intercellular communication, tissue repair, and immune regulation. As we age, the signaling properties of EVs – including exosomes – change significantly, with their molecular makeup altered by mitochondrial dysfunction and increased oxidative stress.

Because EVs from aged cells may carry higher levels of pro-inflammatory signals and lower levels of antioxidant molecules, they can impair tissue repair and promote chronic inflammation. The reduced capacity of aged EVs for beneficial signaling may promote senescence or tissue damage rather than regeneration, and contribute to conditions such as cardiovascular disease, neurodegeneration, and skin aging.

For medical purposes, EVs offer a minimally invasive way to monitor health because they carry surface markers and cargo from their parent cells that can reflect the health status and disease states of the body.

“They’re kind of a unique sentinel that’s reflecting what’s going on in the cell of origin,” says Nobel Laureate Randy Schekman, a professor at UC Berkeley’s Department of Molecular & Cell Biology. “In our body they’re floating around by the trillions in blood and lymph and urine and saliva, and if you can capture them and evaluate the heterogeneity of them you can have a snapshot of what’s going on inside the body.”

Therapeutic Potential

In addition to their role as healthspan indicators, EVs are emerging as important mediators of intercellular communication. Their role in the transmission of biological signals between cells to regulate a diverse range of biological processes is being studied, and scientists are looking into their therapeutic potential against cancer, infectious diseases, and neurodegenerative disorders. EVs from sources including mesenchymal stem cells (MSCs), immune cells, plants, and milk show therapeutic potential across tissue repair, immune modulation, oncology, and neurological disorders.

Plant-derived EVs (PDEVs) from ginger, grape, grapefruit, and broccoli possess exceptional gastrointestinal stability and low immunogenicity, supporting the feasibility of oral administration. Bovine milk-derived EVs exhibit extraordinary stability, resisting gastric acid, digestive enzymes, and thermal processing, enabling oral delivery that may overcome the poor oral bioavailability limitation of most mammalian EVs.

According to recent studies, EVs confer native biocompatibility and stability within biological environments, making them particularly interesting to proponents of longevity medicine. But there are barriers that block the clinical implementation of EV therapy, including limited understanding of biodistribution, dose-response dynamics, and loading efficiency. EVs from different sources show varying levels of promise, and research on their safety and efficacy is still underway.

Before EVs can be approved, there are several developmental priorities that must be met:

The Path to Approval

The global regulatory landscape for EV therapeutics is evolving rapidly, though significant divergence remains across regions and no global consensus exists on standardized critical quality attributes (CQAs). In the European Union, the regulatory pathway for EV products depends on their specific composition, mechanism of action, and intended therapeutic use, with some products potentially falling under the advanced therapy medicinal product (ATMP) framework.

In the U.S., the FDA’s Center for Biologics Evaluation and Research (CBER) oversees EV therapeutics under Section 351 of the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. In August 2025, the National Institutes for Food and Drug Control (NIFDC) published the first official technical review supporting the druggability of EV products.

In Asia, a landmark development occurred in August 2024 when Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) released the Quality and Safety Assessment Report for Extracellular Vesicle Therapeutic Products, representing the world’s first national-level official technical guideline dedicated to EV drug development. In China, the Center for Drug Evaluation (CDE) issued a draft guidance in June 2025 formally incorporating EV therapeutics into the ATMP framework, classifying them as either novel delivery system drugs or cell derivative products based on composition and mechanism.

Concluding Thoughts

Although EVs show enormous potential, they are not yet approved for general therapeutic use. Once scientists and researchers find and demonstrate the best ways to utilize and distribute these small-but-mighty cellular signalers safely and effectively, they may play a key role in emerging therapeutic strategies to monitor disease and extend healthspan and lifespan.

Sources:

Extracellular Vesicles: A Comprehensive Review of Their Origins, Functions, and Therapeutic Potential

Why Extracellular Vesicles Matter

Small Extracellular Vesicles from Young Plasma Reverse Age-related Functional Declines by Improving Mitochondrial Energy Metabolism

Plasma Extracellular Vesicles Carry Immune System-Related Peptides that Predict Human Longevity

Extracellular Vesicles as Next-Generation Therapeutics: Global Pipeline, Regulatory Landscape, and Translational Challenges